pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›tavapadon
drug · small molecule
save

tavapadon

pre_registrationupdated 6mo ago
by $ABBV AbbVie Inc.🔗 ChEMBL
community read0 votes

Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 3 investigational indications.

indications

indications
Parkinson's Disease

targets

D(1A) dopamine receptorD(1B) dopamine receptor

all catalysts(0)

nothing on the calendar yet

Trials studying tavapadon

  • —Expanded Access to Tavapadonavailable
  • phase3Open-label Trial in Parkinson's Disease (PD)completedn=992
  • phase3Flexible-Dose Trial in Early Parkinson's Disease (PD)completedn=304
  • phase3Fixed-Dose Trial in Early Parkinson's Disease (PD)completedn=529
  • phase1A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participantscompletedn=83
  • phase3Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)completedn=507
  • phase1To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Functioncompletedn=14
  • phase1Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Diseasecompletedn=25

News(8)

  • Neurosterix nabs $105M, recruits Karuna veterans for schizophrenia push
    Addex Therapeutics spinout Neurosterix will use the series B funds to advance an oral drug targeting M4, a muscarinic receptor also targeted by BMS’ Cobenfy, which introduced a new mechanism for tr…
    biospace · 4d ago
  • With an approval apiece, the verdict is still out on AbbVie’s and BMS’ twin neuro buys
    After emraclidine’s schizophrenia fail and Cobenfy’s laggard launch, it’s too early to know who made the better buy: AbbVie, in its $8.7 billion Cerevel takeover in late 2023, or Bristol Myers Squi…
    biospace · 8d ago
  • Cerevance Parkinson’s drug shortens 'off time' in Ph. 3, paving path to FDA
    The Takeda spinout showed that a high dose of solengepras can shorten the periods during which difficult Parkinson’s disease symptoms like involuntary movements and sleepiness.
    biospace · 1mo ago
  • Cerevance rescues its Parkinson's drug with phase 3 win
    Cerevance's oral non-dopaminergic therapy has redeemed itself by improving both motor and non-motor symptoms in a phase 3 Parkinson's disease study.
    fiercebiotech · 1mo ago
  • PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval
    A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.
    biopharma_dive · 1mo ago
  • AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeover
    In the Phase 3 TEMPO program, AbbVie’s Juvmo elicited significant improvements in motor symptoms and prolonged periods with good symptom control.
    biospace · 1mo ago
  • AbbVie's next-gen dopamine therapy for Parkinson's gets FDA approval
    The FDA approved AbbVie’s tavapadon, a next-generation therapy for Parkinson’s disease that's expected to provide the symptom relief of its predecessors but with fewer side effects. The dopamine ag…
    endpoints · 1mo ago
  • AbbVie shares pressured as Q2 I&I beat falls below investor expectations
    AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.
    biospace · 3mo ago
generic
tavapadon
MOA
Dopamine D1 receptor partial agonist; Dopamine D5 receptor partial agonist
indication
Parkinson's Disease
phase
pre_registration
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?